{"disease":{"id":"moderate-to-severe-vasomotor-symptoms","name":"moderate to severe vasomotor symptoms"},"drugs":{"marketed":[{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Moderate to severe vasomotor symptoms of menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"elinzanetant","indication_name":"Moderate to severe vasomotor symptoms due to menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ELINZANETANT","company_name":"","drug_phase":"marketed","molecular_target":"NK1, NK3","drug_class":"","quality_score":55,"revenue":null,"mechanism":"LYNKUET blocks NK1 and NK3 receptors, reducing Substance P and Neurokinin B signaling to modulate neuronal activity in thermoregulation."},{"drug_id":"menest","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with the menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"duavee","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with menopause","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"Bazedoxifene Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptors (ER) α and β","drug_class":"Estrogen agonist/antagonist combination","quality_score":65,"revenue":null,"mechanism":"Pairs conjugated estrogens with bazedoxifene to bind and activate estrogen receptors α and β with tissue-specific effects."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05300568","title":"A Survey About Trade-offs When Choosing Menopause Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":1465,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT01015677","title":"A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":99,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}